Phase 3Not yet recruiting
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®
A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Study Comparing the Efficacy and Safety of Semaglutide Injection and Wegovy® for Weight Loss in Obese Subjects
- Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd., (Industry)
- Enrolment
- 370 planned
- Conditions
- Obesity
- Interventions
- Semaglutide; Semaglutide
- Ages
- adults, older adults
- Registry
- NCT06633783
Full record on ClinicalTrials.gov
From the registry
The purpose of the study is to compare the effect on body weight in subjects taking semaglutide injection or subjects taking Wegovy®.
Primary outcomes
- Change in body weight
History
Study completion expected
Primary completion
Started
Registered